The achievement of a significant milestone in the collaboration between Corteva Agriscience and AgPlenus to develop novel herbicides is likely to be viewed positively by investors and could lead to increased optimism about Corteva's future prospects and innovation capabilities in the agricultural sector. This development could potentially enhance Corteva's product portfolio and competitive edge, thus positively impacting its stock price in the short term.

As the parent company of AgPlenus, Evogene Ltd. stands to benefit from the successful milestone achieved in the collaboration with Corteva Agriscience. This progress in developing novel herbicides could be seen as a positive indicator of Evogene's research and development capabilities and its potential for future revenue growth from this venture. Consequently, this news could lead to a positive short-term impact on Evogene's stock price as investors may view this development as a step forward in the company's growth and innovation trajectory.